Abstract
The versatility and potential of reductive cyclisation as a route to 5-membered N-heterocyclic structures of diverse complexity is demonstrated through selected examples.
Keywords: heterocycles, cycloaddition, leimgruber-batcho synthesis, reducing agents, cross-coupling reaction, cytotoxicity, human lung cancer
Current Organic Chemistry
Title: Reductive Cyclisation in the Synthesis of 5-Membered N-Heterocycles
Volume: 8 Issue: 16
Author(s): Petros G. Tsoungas and Andreas I. Diplas
Affiliation:
Keywords: heterocycles, cycloaddition, leimgruber-batcho synthesis, reducing agents, cross-coupling reaction, cytotoxicity, human lung cancer
Abstract: The versatility and potential of reductive cyclisation as a route to 5-membered N-heterocyclic structures of diverse complexity is demonstrated through selected examples.
Export Options
About this article
Cite this article as:
Tsoungas G. Petros and Diplas I. Andreas, Reductive Cyclisation in the Synthesis of 5-Membered N-Heterocycles, Current Organic Chemistry 2004; 8 (16) . https://dx.doi.org/10.2174/1385272043369755
DOI https://dx.doi.org/10.2174/1385272043369755 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Interfering with Protein-Protein Contact: Molecular Interaction Maps and Peptide Modulators
Current Topics in Medicinal Chemistry Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery Antitumor Activity of Polysaccharides: An Overview
Current Drug Targets Plasma-Rich in Growth Factor and its Clinical Application
Current Stem Cell Research & Therapy CDC25 Phosphatase Inhibitors: An Update
Mini-Reviews in Medicinal Chemistry Epigenetic Metalloenzymes
Current Medicinal Chemistry Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Micro-flow Immunosensor Based on Thin-film Interdigitated Gold Array Microelectrodes for Cancer Biomarker Detection
Current Drug Delivery Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors
Medicinal Chemistry Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Regulation of Radiation-Induced Apoptosis by Early Growth Response-1 Gene in Solid Tumors
Current Cancer Drug Targets Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design